文献速递药物相互作用抗栓抗凝管理特殊人群用药

恩扎卢胺对前列腺癌患者依度沙班抗凝治疗的影响

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer.
PubMed 文献 · Br J Clin Pharmacol · 2025-11-23

依度沙班AUC0-24h的几何均值比为1.03(90%CI 0.78-1.35),虽未落在0.8-1.25生物等效区间内,但平均暴露无差异,支持两药安全联用。

要点

  • 恩扎卢胺不改变依度沙班的平均暴露,AUC0-24h GMR为1.03。
  • 90%CI 0.78-1.35超出0.8-1.25,未能确立生物等效性。
  • 依度沙班暴露变异性增大,但预计无临床相关性,支持安全联用。

核心结论

  • 恩扎卢胺不影响依度沙班的平均暴露,但生物等效性未确立,支持两药安全联用。

研究设计与样本

  • 在稳态下测量依度沙班血药浓度,采用非房室分析计算药代动力学参数。

主要发现

  • 联用与不联用恩扎卢胺的患者间,依度沙班暴露相似。
  • 依度沙班AUC0-24h的几何均值比为1.03(90%CI 0.78-1.35)。

关键数值与推荐

  • 若几何均值比90%CI完全落在0.8-1.25范围内,则判定无临床相关相互作用;本研究90%CI为0.78-1.35,超出该范围。

临床怎么用

  • 基于平均暴露无差异且变异性增大预计无临床相关性,可支持恩扎卢胺与依度沙班联用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug-drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants. While low molecular weight-heparin can be safely combined with enzalutamide, the safety of combining enzalutamide with more convenient oral anticoagulants remains uncertain. The objective of this study was to assess whether a drug-drug interaction exists between enzalutamide and edoxaban. METHODS: A prospective, multicentre, two-arm parallel study was performed in men with prostate cancer who are treated with edoxaban, with and without enzalutamide. Plasma concentrations of edoxaban were measured at steady state. Pharmacokinetic (PK) parameters were calculated using non-compartmental analysis. Geometric mean ratios (GMR) of the area under the plasma concentration time curve over one dosing interval (AUC0-24h) were calculated. No clinically relevant interaction was defined if 90% of the confidence interval (CI) of the GMR was within the range of 0.8-1.25. RESULTS: Sixteen patients with prostate cancer using edoxaban (eight patients with enzalutamide and eight patients without enzalutamide) were enrolled. The exposure of edoxaban was similar between patients treated with or without enzalutamide, however the 90% CI fell outside of the 0.8-1.25 range (AUC0-24h GMR 1.03; 90% CI 0.78-1.35). CONCLUSIONS: The average exposure of edoxaban was not affected by enzalutamide. However, bioequivalence could not be established due to the broader than anticipated CI. Despite this, the larger variability in edoxaban exposure is not expected to be clinically relevant, supporting the safe co-administration of both drugs.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Op 't Hoog CJP, Mehra N, van Kleef A, et al. Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer. Br J Clin Pharmacol. 2025. PMID: 41276277. doi:10.1002/bcp.70369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。